We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHV icon
76
Achieve Life Sciences
ACHV
$634M
$3.44M 0.15%
+419
New +$5.15M
MGNX icon
77
MacroGenics
MGNX
$245M
$3.26M 0.14%
149,839
-714
-0.5% -$15K
AGN
78
PUT
DELISTED
Allergan Inc
AGN
$3.1M 0.13%
183
-680
-79% -$106K
QURE icon
79
uniQure
QURE
$2.52B
$3.06M 0.13%
225,081
-128,919
-36% -$1.4M
PARA
80
DELISTED
Paramount Global Class B
PARA
$2.99M 0.13%
+48,100
New +$2.86M
OXGN
81
DELISTED
OXIGENE INC COM
OXGN
$2.88M 0.12%
+1,111,798
New +$3.24M
RIBT
82
DELISTED
RiceBran Technologies
RIBT
$2.86M 0.12%
+54,104
New +$2.88M
IMNN icon
83
PUT
Imunon
IMNN
$6.43M
$2.78M 0.12%
3
– –
VNDA icon
84
CALL
Vanda Pharmaceuticals
VNDA
$310M
$2.75M 0.12%
+1,700
New +$22.6K
TNXP icon
85
Tonix Pharmaceuticals
TNXP
$158M
– –
0
– –
BLUE
86
CALL
DELISTED
bluebird bio
BLUE
$2.66M 0.11%
+53
New +$17K
LUMO
87
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.62M 0.11%
110
-76
-41% -$15.5K
TLPH icon
88
PUT
Talphera
TLPH
$67.5M
$2.61M 0.11%
127
+11
+9% +$2.21K
LPCN icon
89
Lipocine
LPCN
$17.6M
$2.54M 0.11%
+24,512
New +$2.93M
NVAX icon
90
PUT
Novavax
NVAX
$1.21B
$2.52M 0.11%
272
-125
-31% -$11K
VIRX
91
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.48M 0.11%
18
+3
+20% +$3.48K
ARWR icon
92
Arrowhead Research
ARWR
$12.1B
$2.47M 0.11%
+172,353
New +$2.26M
AVNR
93
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$2.45M 0.11%
+434,000
New +$2M
XNCR icon
94
Xencor
XNCR
$1.48B
$2.44M 0.1%
+209,686
New +$2.06M
INCY icon
95
CALL
Incyte
INCY
$26B
$2.43M 0.1%
431
-615
-59% -$31.4K
ARNA
96
PUT
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.4M 0.1%
410
+134
+49% +$8.44K
SLXP
97
PUT
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$2.33M 0.1%
189
+41
+28% +$4.53K
RVNC
98
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.29M 0.1%
+67,200
New +$2.11M
RXII
99
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$2.19M 0.09%
7,156
-4,626
-39% -$1.42M
ACAD icon
100
PUT
Acadia Pharmaceuticals
ACAD
$4.45B
$2.17M 0.09%
960
+627
+188% +$13.1K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.